Maria de Miguel - HM Sanchinarro University Hospital

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 69 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

Bob T Li,Funda Meric-Bernstam,Aditya Bardia,Yoichi Naito,Salvatore Siena,Philippe Aftimos, Ian Anderson,Giuseppe Curigliano,Maria de Miguel, Maitri Kalra,Do-Youn Oh,Joon Oh Park,

The Lancet Oncology (2024)

引用0浏览0引用

The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives

Miriam Dorta-Suarez,Maria de Miguel, Oscar Amor-Carron, Jose Miguel Calderon, Mcarmen Gonzalez-Ortega,Delvys Rodriguez-Abreu

CANCER TREATMENT REVIEWS (2024): 102671-102671

引用0浏览0WOS引用

Abstract PO1-26-02: Enfortumab vedotin (EV): Correlation of estrogen receptor status and Nectin-4 expression with single agent efficacy in breast XPDX models

Crystal Moreno, Johnnie Flores, Alyssa Simonson, Maci DeBoer, Natalia Banos, Armando Diaz III, Morgan Lynch, Jim Lund, Leonora Leykum, Tahmi Rouzbahan, Manuel Pedregal, Kyriakos P. Papadopoulos,

Cancer Researchno. 9_Supplement (2024): PO1-26

引用0浏览0引用

Abstract CT095: Phase 1 evaluation of triple therapy with boserolimab (anti-CD27 agonist), pembrolizumab, and chemotherapy in patients with triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) <10: Safety, antitumor activity, and association between biomarkers and response

Carlos Rojas, Bernard Gaston Doger de Spéville,Seock-Ah Im,Ronnie Shapira-Frommer,María De Miguel,Lucía González Cortijo, Margarita Romeo Marin,Maja de Jonge, Mark Ayers, Yiwei Zhang, Song Zhai,Elliot Chartash,

Cancer Researchno. 7_Supplement (2024)

引用0浏览0引用

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Amita Patnaik, Silvia Antolin Novoa, Meritxell Bellet- Ezquerra,Francois-Clement Bidard,Valentina Boni, Maxime Brunet, Mario Campone, Carlos Garay, Raquel Gómez-Bravo,Sacha Howell, Rinath Jeselsohn,Simon Lord,

Cancer Researchno. 9_Supplement (2024): PO3-04

引用0浏览0引用

Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

Bob T Li,Funda Meric-Bernstam,Aditya Bardia,Yoichi Naito,Salvatore Siena,Philippe Aftimos, Ian Anderson,Giuseppe Curigliano,Maria de Miguel, Maitri Kalra,Do-Youn Oh,Joon Oh Park,

The Lancet. Oncology (2024)

引用0浏览0WOS引用

Short or long-term treatment with CDK4/6 inhibitors in patients with ER plus breast cancer: characterization and comparative analysis of resistance in seventeen XPDX models

Alyssa Simonson, Johnnie Flores, Morgan Lynch, Emily Carpenter, Justine Hruzek, Jim Lund, Natalia Banos Herraiz,Kyriakos Papadopoulos, Amy Vander Woude,Gladys Rodriguez,Sreenivasa Chandana, Thomas Gribbin,

CANCER RESEARCHno. 7 (2023)

引用0浏览0引用

Initial results from the phase 2A trial of visugromab (CTL-002) + nivolumab in advanced/ metastatic anti-PD1/-L1 relapsed/refractory solid tumors (The GDFATHER-TRIAL)